Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Neoprobe Neoprobe 1000 study

This article was originally published in The Gray Sheet

Executive Summary

Neoprobe Neoprobe 1000 study: Gamma radiation detecting device employed in a lymphatic breast cancer mapping study by John Albertini, MD, University of South Florida, et al. published in the Dec. 11 Journal of the American Medical Association. The study of 62 patients with newly diagnosed invasive breast cancers found that lymphatic mapping was possible and that histologic characterization of the first lymph node to the primary tumor predicts characteristics of the remaining lymph nodes. "Lymphatic mapping and selective lymphadenectomy could lead to more conservative surgical treatment of women with breast cancer," Albertini et al. conclude. The Neoprobe 1000 was 510(k) cleared in December 1986 for radiation detection, and is used in conjunction with the firm's RIGSCAN CR49 radioimmuno-guided surgery system. The company plans to submit a biologic licensing application for detection of metastatic colorectal cancer ("The Gray Sheet" Oct. 21, p. 9)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT007269

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel